Combination of Sotyktu and Enstilar for Plaque Psoriasis

Prior treatment

• Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
• Use of oral systemic medications or PUVA phototherapy for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).
• Prior use of biologics within the following periods:
  • Etanercept - 4 weeks
  • Adalimumab or certolizumab pegol - 8 weeks
  • IL-17 antagonists - 16 weeks
  • Ustekinumab or IL-23 pathway inhibitors - 24 weeks
  • Other biologics - 5 half-lives
• Patient used topical therapies or UVB phototherapy to treat psoriasis within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).

Other illness

• Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.

• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type psoriasis
• Moderate to severe plaque type psoriasis as defined at baseline by:
  • BSA affected by plaque-type psoriasis of 10% or greater
  • PGA score of 3 or greater
  • PASI ≥ 12.
• Able and willing to give written informed consent prior to performance of any study-related procedures Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.